<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571739</url>
  </required_header>
  <id_info>
    <org_study_id>999912036</org_study_id>
    <secondary_id>12-I-N036</secondary_id>
    <nct_id>NCT01571739</nct_id>
  </id_info>
  <brief_title>Determining Risk in Latent Tuberculosis</brief_title>
  <official_title>Risk Stratification in Latent Tuberculosis: PET/CT Findings in TB Contacts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Tuberculosis (TB) is a leading cause of death worldwide. Those who are exposed to the TB
      bacteria but have not become sick are said to have latent TB. Many people with latent TB will
      not get sick from it, but some people will develop active TB and become sick. Much is known
      about how to treat and diagnose active TB, but little is known about the best way to treat
      latent TB. Researchers also want to know more about the risk that latent TB will develop into
      active TB, and whether it is possible to test for this risk.

      Objectives:

      - To test possible methods of determining a person s risk for developing active TB.

      Eligibility:

      - Individuals between 20 and 60 years of age who (1) have active TB, (2) were exposed to
      someone with active TB in the past 9 months, or (3) have not been exposed to TB.

      Design:

        -  Participants will be separated into groups based on their exposure to TB.

        -  Healthy participants who were not exposed to TB will answer questions about their
           medical history. They will also provide blood and urine samples.

        -  Participants who have active TB will have a physical exam and medical history. They will
           provide blood, urine, and sputum samples, and will have a chest x-ray. They will be
           treated with the standard of care for active TB. Some participants with active TB may
           have additional tests as part of this study.

        -  Participants who were exposed to TB and have latent TB will have a physical exam and
           medical history. They will provide blood, urine, and sputum samples, and will have a
           chest x-ray. They will be asked to return for five more clinic visits over the next 12
           months to repeat these tests. They may also have additional chest imaging studies
           depending on the study needs.

        -  Some of the exposed participants may have been exposed to drug-resistant TB. These
           participants will receive the drug isoniazid to take on a regular schedule to help
           prevent the latent TB from becoming active TB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of treating tuberculin skin test (TST) positive, or interferon gamma release
      assay (IGRA) positive, contacts of tuberculosis (TB) cases to prevent progression to disease
      is well established. However the length of treatment, and the toxicity associated with the
      currently used regimens, means that the risk may outweigh the benefit and treatment
      completion rates are poor. In addition, no proven regimens are available for contacts of
      multidrug resistant tuberculosis (MDR-TB) cases. Because as few as 2% of contacts develop
      active TB over 1 year and no surrogate markers are available, drug trials to assess novel
      treatments typically require thousands of subjects followed up for many years.
      (18F)-fluoro-2-deoxy-D-glucose positron emission tomography/computer tomography (FDG-PET/CT)
      may prove a useful surrogate for more targeted chemoprophylaxis as well as a means to rapidly
      evaluate novel prophylactic regimes in future studies.

      Up to 40% of immune-sensitized TB contacts with normal chest radiographs (CXR) have
      abnormalities on conventional chest CT. FDG-PET/CT not only will allow characterization of
      the metabolic activity of these lesions but is also likely to reveal significantly increased
      metabolic activity within regional lymph nodes that may otherwise be anatomically normal.
      Based on previous studies, we predict that up to 65% of contacts will have combined chest
      PET/CT abnormalities and that up to 50% of contacts who are treated, will have increased FDG
      uptake that will resolve with treatment. By contrast, PET screening studies demonstrate
      abnormal pulmonary FDG uptake occurs in 0.9% of healthy individuals.

      The development of biomarkers more predictive of disease progression is also highly
      desirable, but for similar reasons evaluating them is challenging. This novel approach of
      using FDG-PET/CT to benchmark the dynamic immunological, transcriptional, or metabolic
      changes that occur early in tuberculosis infection, we hope will accelerate biomarker
      discovery. In this study we propose to evaluate these predictions in order to lay the
      foundation for future studies.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2, 2012</start_date>
  <completion_date>May 20, 2014</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the rate of PET plus CXR at baseline among all study participants.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the rate of PET+/CT- at baseline among all study participants.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the rate of regression of PET plus scans (to normal) at 3 and 12 months among the untreated subjects (n=30).</measure>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Latent Tuberculosis</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INDEX CASES:

        INCLUSION CRITERIA:

          1. Either confirmed sputum smear positive and culture positive for M. tb within the last
             12 months OR sputum smear positive and genotypically confirmed M.tb with culture
             awaited

          2. Age greater than or equal to 20 years old

        20 Smear Positive Pulmonary TB Biomarker Index Case Controls:

        INCLUSION CRITERIA:

          1. Genotypically confirmed sputum smear positive pulmonary tuberculosis

          2. Culture awaited or confirmed Mtb

          3. Not commenced anti-tuberculous therapy

          4. Age greater than or equal to 20 years old

        EXCLUSION CRITERIA:

          1. Age &gt;60 years old

          2. Known diagnosis of chronic inflammatory condition (e.g. Sarcoid, RA, connective tissue
             disorder) or on immunosuppressive medication

        WITHDRAWAL CRITERIA:

        1) Culture negative for M.tb

        QF-GIT Positive Contacts:

        INCLUSION CRITERIA:

          1. Contacts of index case

          2. QF-GIT positive

          3. Age greater than or equal to 20 years old

          4. Normal CXR

        EXCLUSION CRITERIA:

          1. Exposure to an index case who commenced treatment for a current episode of TB (one
             that was not successfully treated, per WHO definition) more than 15 months ago

          2. Previously diagnosed or treated TB

          3. Symptoms or signs of active TB

          4. Symptoms or signs of acute illness

          5. CXR suggestive of active tuberculosis or parenchymal abnormalities known or suspected
             to be caused by alternative pathology

          6. HIV positive or other significant immunocompromise

          7. Age &gt;60

          8. Smoker &gt;30 pack years

          9. Previously diagnosed malignancy

         10. Previously diagnosed chronic lung infection (e.g., non tuberculosis mycobacteria
             [NTM], Fungal, Paragonimus)

         11. Known diagnosis of chronic inflammatory condition associated with pulmonary pathology
             (e.g., Sarcoidosis, RA, Wegener s granulomatosis, bronchiectasis)

         12. Inhaled or systemic steroid use within previous 2 weeks (subject may return for
             enrollment 2 weeks after last dose) and need for ongoing steroid therapy

         13. Breast feeding, pregnant, or planning pregnancy

         14. Anticipated poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifton E Barry, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer. 2011 Jul 12;6(1):11. doi: 10.1186/1750-9378-6-11.</citation>
    <PMID>21749691</PMID>
  </reference>
  <reference>
    <citation>Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagu√© X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135-45.</citation>
    <PMID>17079588</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009. MMWR Morb Mortal Wkly Rep. 2010 Aug 20;59(32):1018-23.</citation>
    <PMID>20724968</PMID>
  </reference>
  <verification_date>May 20, 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2012</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <keyword>Biomarker</keyword>
  <keyword>Latent Tuberculosis</keyword>
  <keyword>IGRA</keyword>
  <keyword>Isoniazid</keyword>
  <keyword>TB Lymphadenopathy</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>TB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

